![](\"https:\/\/mms.businesswire.com\/media\/20260925755806\/en\/2912304\/4\/miradx_logo.jpg\"){kind=logo}
<\/a><\/a><\/p>\nLOS ANGELES–(BUSINESS WIRE)–#ASTRO26<\/a>–MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced that research supporting its PROSTOX technology and the role of germline biomarkers in predicting treatment-related adverse events and response will be featured in five presentations and educational sessions at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, Mass.<\/p>\n \nThe presentations reflect a growing body of evidence about the genetic underpinnings of differences in radiation sensitivity and how they can help physicians identify patients at greater risk of late-onset adverse events as well as treatment responses. This knowledge could support more personalized treatment choices.<\/p>\n \nA key highlight will be new data presented by Amar Kishan, MD, Professor and Executive Vice Chair for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and UCLA Jonsson Comprehensive Cancer Center, and Chair of the American Society for Radiation Oncology (ASTRO) Prostate\/GU Resource Panel. These findings, drawn from a cohort of multiple prospective clinical trials including the landmark PACE-B trial, validate the germline biomarker used in MiraDx\u2019s PROSTOX tests to predict late genitourinary (GU) adverse events in a fractionation-specific manner following radiotherapy for localized prostate cancer. A mediation analysis performed on a prospective clinical utility study showed that use of the PROSTOX tests resulted in an absolute 17.5% reduction in 2+ late GU adverse events.<\/p>\n \nAdditional research presented by Joanne Weidhaas, MD, PhD, Professor of Radiation Oncology and Vice Chair of Molecular and Cellular Oncology at the David Geffen School of Medicine at UCLA and co-founder of MiraDx, demonstrates the ability of MiraDx\u2019s PROSTOX test to predict late GU adverse events following stereotactic body radiation therapy (SBRT) to the prostate fossa after radical prostatectomy. Her research also describes the role of microRNA (miRNA) variations identified by PROSTOX testing in the regulation of global messenger RNA (mRNA) and miRNA expression patterns across key cellular pathways.<\/p>\n \nBeyond prostate cancer, Weidhaas will present research examining genetic signatures associated with adverse events and overall survival in patients with head and neck squamous cell carcinoma receiving radiation therapy and cisplatin chemotherapy. She is also participating in an educational session and presenting on germline miRNA signatures and their role in predicting radiation treatment toxicity.<\/p>\n \n\u201cAs cancer treatment becomes more targeted and complex, we need predictive tools based on an individual\u2019s personal genetics to identify optimal treatment pathways, including those predicting who is at increased risk for treatment-related adverse events,\u201d said Dr. Weidhaas. \u201cOur genetics can help determine how susceptible we are to these side effects. Understanding not only which genetic biomarkers contribute to that risk, but also how those biomarkers impact gene expression and biological processes gives insights into why patients receiving the same treatment can experience very different outcomes.\u201d<\/p>\n \nASTRO 2026 Presentations<\/p>\n \nEDU 08 – Biomarkers to Predict Radiation Treatment Toxicity \nPQA 03 – Digital Health Innovation and Informatics, Patient Safety & Quality, and Radiation and Cancer Biology \nSS 36 – Predicting Benefit and Toxicity: Biomarkers in Prostate Radiotherapy \nQP 28 – Actionable Biomarkers: Guiding Therapy Selection and Deescalation \nQP 40 – Personalized Therapy and Special Populations in Head and Neck Cancer \nMeet the Investigators<\/p>\n \nAmar Kishan, MD, Professor and Executive Vice Chair for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and UCLA Jonsson Comprehensive Cancer Center, and Chair of the American Society for Radiation Oncology (ASTRO) Prostate\/GU Resource Panel, will present research validating a germline biomarker for late GU adverse events following prostate cancer radiotherapy.<\/p>\n \nJoanne Weidhaas, MD, PhD, Professor of Radiation Oncology and Vice Chair of Molecular and Cellular Oncology at the David Geffen School of Medicine at UCLA and co-founder of MiraDx, will present four studies focused on miRNA-based genetic predictors of radiation outcomes.<\/p>\n \nAbout MiraDx<\/p>\n \nMiraDx is a molecular diagnostics company that specializes in developing tests that support individualized cancer treatment. By analyzing an individual\u2019s unique miRNA-based germline signatures, MiraDx enables clinicians and their patients to optimize therapeutic decision choices across radiation therapy, chemotherapy, and immunotherapy. Its tests offer a first-of-their-kind ability to predict treatment-related outcomes based on the patient, facilitating more informative, personalized cancer care.<\/p>\n \nTo learn more about MiraDx and PROSTOX, visit https:\/\/miradx.com<\/a>.<\/p>\n Contacts <\/p>\n \nPartnership and Other General Inquiries, info@miradx.com<\/a><\/p>\n Media Contact, media@miradx.com<\/a><\/p>\n
\n
Title: Germline microRNA-Based Signatures to Predict Radiation Treatment Toxicity<\/a>
Presenter: Joanne Weidhaas, MD, PhD
\n
Date\/Time: September 27, 2026, 5:17-5:32 p.m. ET
\n
Location: Room 156<\/p>\n
\n
Title: mRNA and miRNA Expression Differences Between High- and Low-Risk PROSTOX Patients<\/a>
Presenter: Joanne Weidhaas, MD, PhD
\n
Date\/Time: September 28, 2026, 10:45 a.m.-12:00 p.m. ET
\n
Location: Poster Hall – Exhibit Hall A, Screen 4<\/p>\n
\n
Title: Germline Biomarker for Late Genitourinary Adverse Events after Radiotherapy for Prostate Cancer: Validation in Multiple Prospective Trials<\/a>
Presenter: Amar Kishan, MD
\n
Date\/Time: September 29, 2026, 5:45 p.m. ET
\n
Location: Room 210<\/p>\n
\n
Title: Germline Biomarker Predicts Adverse Events Following SBRT to the Prostate Fossa After Radical Prostatectomy<\/a>
Presenter: Joanne Weidhaas, MD, PhD
\n
Date\/Time: September 29, 2026, 5:40-5:45 p.m. ET
\n
Location: Room 205<\/p>\n
\n
Title: Genetic Signatures Predicting Toxicity and Overall Survival in Head and Neck Squamous Cell Carcinoma<\/a>
Presenter: Joanne Weidhaas, MD, PhD
\n
Date\/Time: September 30, 2026, 9:20-9:25 a.m. ET
\n
Location: Room 156<\/p>\n